Scientist.com

In 2024, the biotherapeutics industry made significant progress in transforming disease treatment, one example being the landmark approval of CASGEVY®, the first cell-based gene therapy for the treatment of transfusion-dependent beta-thalassemia.

In this Q&A, Dr. Francisca Neethling, Head of Biotherapeutic Services at Eurofins Discovery, shares the highs and lows of the past year, the team’s successes and what to expect in 2025. Read it now: https://app.scientist.com/blog/2024/12/12/the-year-in-review-biotherapeutics-in-2024-and-a-look-ahead-to-2025

"Make genome editing easier" is the goal of Ubigene Biosciences. How are their products and services making this a reality? Find out in our latest edition of Supplier Spotlight®: https://app.scientist.com/blog/2024/12/05/ubigene-biosciences

Get to know Indivumed Services, your partner for biomarker discovery and drug and CDx development to realize personalized oncology. In this edition of Supplier Spotlight®, we asked them a few questions about their service offerings, what problems they help solve, new product and service developments & more.

Read the full blog post now: https://app.scientist.com/blog/2024/12/03/indivumed-services

Crown Bioscience

Introducing Tissue 2 Target, a one-stop service wherein you can procure high-quality, well-characterized human biospecimens and obtain advanced genomic analysis of the samples seamlessly and effectively.

Read the full blog post to learn more about this partnership between Cureline, Inc and Cellecta, Inc. as well as to access their case study on identifying putative biomarkers for rheumatoid arthritis, here: https://app.scientist.com/blog/2024/12/02/tissue-2-target

Epigenomics is rapidly gaining recognition as a crucial approach in the field of cancer research.

Learn how Hologic Diagenode contributed their two decades of epigenomic knowledge to developing an early-detection workflow for colorectal cancer (CRC) that utilizes liquid biopsies, in collaboration with Universal Diagnostics (UDx). Read the full blog here: https://app.scientist.com/blog/2024/11/27/using-dna-methylation-for-advancements-in-early-cancer-detection

In a recent Nature article, Andrew Bradbury and Andreas Plückthun call for a shift in standard research methods toward the use of properly validated, recombinant protein binding reagents. That's where Miltenyi Biotec comes in. Learn how their REAfinity Antibodies are designed for structural standardization, lot-to-lot homogeneity and high binding specificity. Read the full blog post here: https://app.scientist.com/blog/2024/11/25/the-best-antibody-is-the-best-fit

Cell viability is an essential measurement in research areas like drug discovery, toxicology, cancer biology and immunotherapy—understanding this measurement is key to evaluating how cells thrive or die under different conditions.

In this blog post, BPS Bioscience shares what factors to consider when choosing a viability assay and more! Read it here: https://app.scientist.com/blog/2024/11/21/live-step-cell-assay-system-redefining-simplicity-and-accuracy-in-high-throughput-cell-viability-assays

We are proud to announce that our Founder and CEO, Kevin Lustig, has been included on the SD500 list of "The Most Influential People in San Diego" 👏 Thank you to the San Diego Business Journal for the recognition, and congratulations to everyone that made it on the list!

Find the full list in this week's issue, here: https://www.sdbj.com/

Immune checkpoint inhibitors (ICIs) have revolutionized treatment for advanced solid tumors, but challenges like resistance and limited response rates persist. Learn how antibody arrays are showing great potential for advancing precision medicine in ICI therapy by enabling biomarker-based personalization, in our latest blog post with RayBiotech: https://app.scientist.com/blog/2024/11/19/blood-proteomics-revealing-clues-about-immune-checkpoint-therapy-response

Understanding the immune system’s response to drugs is key in fields like cancer immunotherapy, autoimmune diseases and infectious diseases. A key player in these studies? Peripheral Blood Mononuclear Cells (PBMCs).

Dive into our latest blog post to learn more about how PBMCs are isolated and analyzed by Mediford Corporation so they can be utilized for immunology research and vaccine development. Read it here: https://app.scientist.com/blog/2024/11/14/precision-in-pbmc-isolation-and-analysis-driving-next-gen-therapeutic-solutions

To be humanized or not to be? That is the question...

In today's blog post, AvantGen discusses how camelid antibodies have emerged as an exciting alternative for antibody therapeutics, their distinct advantages, whether or not humanization is necessary & more!

Read the full blog post, here: https://app.scientist.com/blog/2024/11/12/to-be-humanized-or-not-to-be-that-is-the-question-for-camelid-vhh-antibodies

Honoring the courage, dedication and sacrifice of the veterans who have served our country and continue to inspire us every day. We are proud to have such incredible individuals as part of our team here at Scientist.com and grateful to all veterans for their unwavering commitment!